Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes

Journal of Endocrinology

Volumn 220, Issue 3, 2014, Pages 233-246

  Chiu, Chiung Zuan ^a,b   Wang, Bao Wei ^a   Shyu, Kou Gi ^b,c  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiac hypertrophy; Hypoxia; Reactive oxygen species; Transcriptional activity

Indexed keywords

CARDIAC HYPERTROPHY; HYPOXIA; REACTIVE OXYGEN SPECIES; TRANSCRIPTIONAL ACTIVITY;

ANGIOTENSIN II; ANIMALS; ANOXIA; CARDIOMEGALY; CELLS, CULTURED; COLLAGEN; HUMANS; MAP KINASE SIGNALING SYSTEM; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; UROTENSINS;

EID: 84894291130     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0261     Document Type: Article

References (52)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW et al. 1999 Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 282-286. (doi:10.1038/45809)
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Tolle M, van der Giet M 2008 Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 29 743-763. (doi:10.1016/j.peptides.2007.08.029)
3. Bai XY, Liu XC, Yang Q, Tang XD & He GW2011 The interaction between human urotensin II and vasodilator agents in human internal mammary artery with possible clinical implications. Annals of Thoracic Surgery 92 610-616. (doi:10.1016/j.athoracsur.2011.03.094)
4. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R 2004 Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regulatory Peptides 120 5-13. (doi:10.1016/j.regpep.2004.04.004)
5. Bousette N& Giaid A 2006 Urotensin-II and cardiovascular diseases. Current Hypertension Reports 8 479-483. (doi:10.1007/s11906-006-0026-7)
6. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA & Giaid A 2006 Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. Journal of Molecular and Cellular Cardiology 41 285-295. (doi:10.1016/j.yjmcc.2006.05.008)
7. Chang H, Shyu KG, Wang BW & Kuan P 2003 Regulation of hypoxiainducible factor 1-a by cyclical mechanical stretch in rat vascular smooth muscle cells. Clinical Science 105 447-456. (doi:10.1042/ CS20030088)
8. Chen K, Mehta JL, Li D, Joseph L & Joseph J 2004 Transforming growth factor β receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circulation Research 95 1167-1173. (doi:10.1161/01.RES.0000150369.68826.2f)
9. Chen SC, Cheng JJ, Hsieh MH, Chu YL, Kao PF, Cheng TH & Chan P 2005 Molecular mechanism of the inhibitory effect of trilinolein on endothelin-1-induced hypertrophy of cultured neonatal rat cardiomyocytes. Planta Medica 71 525-529. (doi:10.1055/s-2005-864153)
10. Chen YL, Liu JC, Loh SH, Chen CH, Hong CY, Chen JJ & Cheng TH 2008 Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. European Journal of Pharmacology 593 24-29. (doi:10.1016/j.ejphar.2008.07.025)
11. Chiu CZ, Wang BW, Chun TH & Shyu KG 2010 Angiotensin II the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat cardiomyocytes. Clinical Science 119 273-282. (doi:10.1042/ CS20100084)
12. Chiu CZ, Wang BW & Shyu KG 2012 Use of atorvastatin to inhibit hypoxiainduced myocardin expression. European Journal of Clinical Investigation 42 564-571. (doi:10.1111/j.1365-2362.2011.02628.x)
13. Dai HY, Guo XG, Ge ZM, Li ZH, Yu XJ, Tang MX & Zhang Y 2008 Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. Journal of Diabetes and its Complications 22 137-143. (doi:10.1016/ j.jdiacomp.2006.10.008)
14. Djordjevic T, BelAiba RS, Boncello S, Pfeilschifter J, Hess J & Gorlach A 2005 Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arteriosclerosis, Thrombosis, andVascular Biology 25 519-525. (doi:10.1161/01.ATV.0000154279. 98244.eb)
15. Dougherty CJ, Kubasiak LA, Freazier DP, Li H, Xiong WC, Bishopric NH & Webster KA 2004 Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. FASEB Journal 181060-181070. (doi:10.1096/fj.04-1505com July 2004)
16. Douglas SA, Tayara L, Ohlstein EH, Halawa N & Giaid A 2002 Congestive heart failure and expression of myocardial urotensin II. Lancet 359 1990-1997. (doi:10.1016/S0140-6736(02)08831-1)
17. Fontes-Sousa AP, Pires AL, Monteiro-Cardoso VF & Leite-Moreira AF 2009 Urotensin II-induced increase in myocardial distensibility is modulated by angiotensin II and endothelin-1. Physiological Research 58 653-660.
18. Gao S, Oh YB, Shah A, Park WH, Chung MJ, Lee YH & Kim SH 2010 Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats. American Journal of Physiology. Heart and Circulatory Physiology 299 H1782-H1789. (doi:10.1152/ajpheart. 00438.2010)
19. Gould PS, Gu M, Liao J, Ahmad S, Cudmore MJ, Ahmed A & Vatish M 2010 Upregulation of urotensin II receptor in preeclampsia causes in vitro: placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. Hypertension 56 172-178. (doi:10.1161/ HYPERTENSIONAHA.110.152074)
20. Gruson D, Rousseau MF, Ahn SA, van Linden F & Ketelslegers JM 2006 Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 1527-1531. (doi:10.1016/ j.peptides.2005.11.019)
21. Guzy RD & Schumacker PR 2006 Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Experimental Physiology 91 807-819. (doi:10.1113/expphysiol. 2006.033506)
22. Huang H, Gong YS, Fan XF, Hu LG, Luo JF & Wu XM 2006 Expression of urotensin II and its receptor on right ventricle in rats of pulmonary hypertension. Zhongguo Ying Yong Sheng Li Xue Za Zhi 22 81-84.
23. Inamoto S, Hayashi T, Tazawa N, Mori T, Yamashita C, Nakano D, Sohmiya K, Okada Y, Kitaura Y & Matsumura Y 2006 Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. Circulation Journal 70 787-792. (doi:10.1253/circj.70.787)
24. Khan SQ, Bhandari SS, Quinn P, Davies JE & Ng LL 2007 Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. International Journal of Cardiology 117 323-328. (doi:10.1016/j.ijcard.2006.05.016)
25. Kontaraji JE, Parthenakis FI, Patrianakos AP, Karalis IK & Vardas PE 2007 Altered expression of early marker genes in circulating cells of patients with hypertrophic cardiomyopathy. Cardiovascular Pathology 16 329-335. (doi:10.1016/j.carpath.2007.04.004)
26. Laderoute KR & Webster KA 1997 Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circulation Research 336.
27. Lamarre NS & Tallarida RJ 2008 A quantitative study to assess synergistic interactions between urotensin II and angiotensin II. European Journal of Pharmacology 586 350-351. (doi:10.1016/j.ejphar. 2008.02.071)
28. Li J, Wang J, Russell FD & Molenaar P 2005 Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. British Journal of Pharmacology 145 432-440. (doi:10.1038/ sj.bjp.0706217)
29. Liu JC, Chen CH, Chen JJ & Cheng TH 2009 Urotensin II induces rat cardiomyocyte hypertrophy via the transient oxidization of src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor. Molecular Pharmacology 76 1186-1195. (doi:10.1124/mol.109.058297)
30. MacLeanMR, Alexander D, Stirrat A, GallagherM, Douglas SA, Ohlstein EH, Morecroft I& Polland K 2000 Contractile response to human urotensin- II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. British Journal of Pharmacology 130 201-204. (doi:10.1038/sj.bjp.0703314)
31. McLennan HR & Degli Esposti M 2000 The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. Journal of Bioenergetics and Biomembranes 32 153-162. (doi:10.1023/ A:1005507913372)
32. Ng LL, Loke I, O'Brien R, Squire IB & Davies JE 2002 Plasma urotensin in human systolic heart failure. Circulation 106 2877-2880. (doi:10.1161/ 01.CIR.0000044388.19119.02)
33. Ni YG, Berenji K, Wang N, Oh M, Sachan N, Dey A, Cheng J, LuG, Morris DJ, Castrillon DH et al. 2006 Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation 114 1159-1168. (doi:10.1161/CIRCULATIONAHA.106.637124)
34. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG 2004 Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Molecular Endocrinology 18 2344-2354. (doi:10.1210/ me.2003-0309)
35. Pakala R 2008 Role of urotensin II in atherosclerotic cardiovascular diseases. Cardiovascular Revascularization Medicine 9 166-178. (doi:10.1016/j.carrev.2008.02.001)
36. Papadopoulos P, Bousette N, Giaid A 2008 Urotensin-II and cardiovascular remodeling. Peptides 29 764-769. (doi:10.1016/j.peptides. 2007.09.012)
37. Prosser HC, Forster ME, Richards AM & Pemberton CJ 2008 Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. Peptides 29 770-777. (doi:10.1016/j.peptides.2007.08.013)
38. Segain JP, Rolli-Derkinderen M, Gervois N, de la Bletiere DR, Loirand G & Pacaud P 2007 Urotensin II is a new chemotactic factor for UT receptorexpressing monocytes. Journal of Immunology 179 9019.
39. Seta KA & Millhorn DE 2004 Functional genomics approach to hypoxia signaling. Journal of Applied Physiology 96 765-773. (doi:10.1152/ japplphysiol.00836.2003)
40. Shyu KG, Chen CC, Wang BW & Kuan P 2001 Angiotensin II receptor antagonist blocks the expression of connexin43 induced by cyclical mechanical stretch in cultured neonatal rat cardiac myocytes. Journal of Molecular and Cellular Cardiology 33 691-698. (doi:10.1006/jmcc.2000. 1333)
41. Shyu KG, Wang BW, Chen WJ, Kuan P & Lin CM 2012 Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast. European Journal of Clinical Investigation 42 16-64. (doi:10.1111/j.1365-2362.2011.02549.x)
42. Song N, Ding W, Chu S, Zhao J, Dong X, Di B & Tang C 2012 Urotensin II stimulates vascular endothelial growth factor secretion from adventitial fibroblasts in synergy with angiotensin II. Circulation Journal 76 1267-1273. (doi:10.1253/circj.CJ-11-0870)
43. Tang WH, Shrestha K, Martin MG, Borowski AG, Jasper S, Yandle TG, Richards AM, Klein AL & Troughton RW 2010 Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure. Journal of Cardiac Failure 16 635-640. (doi:10.1016/j.cardfail. 2010.03.011)
44. Tolle M & van der Giet M 2008 Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 29 743-763. (doi:10.1016/j.peptides.2007.08.029)
45. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE & Krum H 2003 Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circulation Research 93 246-253. (doi:10.1161/01.RES.0000084382. 64418.BC)
46. Wang YX, Ding YJ, Zhu YZ, Shi Y, Yao T & Zhu YC 2007 Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. American Journal of Physiology. Heart and Circulatory Physiology 292 H348-H359. (doi:10.1152/ajpheart. 00512.2006)
47. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak CJ, Nakano D, Sohmiya K, Okada Y, Kitaura Y & Matsumura Y 2007 Angiotensin II receptor blocker reduces oxidative stress and attenuateshypoxia-induced left ventricular remodeling in apolipoprotein Eknockout mice. Hypertension Research 30 1219-1230. (doi:10.1291/ hypres.30.1219)
48. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z, Du J & Tang C 2002 Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart and Vessels 16 64-68. (doi:10.1007/ s380-002-8319-2)
49. Zhang YG, Li YG, Liu BG, Wei RH, Wang DM, Tan XR, Bu DF, Pang YZ & Tang CS 2007 Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacologica Sinica 28 36-43. (doi:10.1111/j.1745-7254.2007.00485.x)
50. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, JungerW, Brohi K, Itagaki K & Hauser CJ 2010 Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 104-107. (doi:10.1038/ nature08780)
51. Zhou P, Wu SY, Yu CF, Wang H, Tang CS, Lin L & Yuan WJ 2003 Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion. Sheng Li Xue Bao: Acta Physiologica Sinica 55 442-448.
52. Zhu YC, Zhu YZ & Moore PK 2006 The role of urotensin II in cardiovascular and renal physiology and diseases. British Journal of Pharmacology 148 884-901. (doi:10.1038/sj.bjp.0706800)